Clinical review for general practice

ISSN (Print) 2713-2552
ISSN (Online) 2782-5671
  • Home
  • about
  • archives
  • contacts
left
FULLSCREEN > Archive > 2025 > Vol 6, №11 (2025) > Beyond the menopause horizon: searching for the clinical onset of cardiometabolic risk

Beyond the menopause horizon: searching for the clinical onset of cardiometabolic risk

Dmitry S. Ruyatkin , Lyudmila A. Ruyatkina , Liliya V. Shcherbakova

For citation:


  • Abstract
  • About the Author
  • References

Abstract

The critical role of insulin resistance (IR), closely associated with abdominal obesity (AO), in the initiation and progression of cardiometabolic risk (CMR) during perimenopause necessitates studying the associations of waist circumference (WC), a clinical marker of AO, with parameters of menopausal metabolic syndrome (MetS).
Aim. To study the relationships between waist circumference, the TyG index, MetS characteristics, and the hormonal chronology of perimenopause in a cohort of women with different blood pressure (BP) levels.
Materials and methods. Of the 88 women aged 35–59 years, 58 had hypertension and 30 were normotensive. The following parameters were determined: WC, blood pressure, triglycerides (TG), HDL-C, insulin, follicle-stimulating hormone (FSH), estradiol, glucose, TyG index, and postmenopausal duration (PMD). The following parameters were assessed (SPSS, version 23): median [25th; 75th percentiles]; intergroup differences using the Mann-Whitney test; comparison of proportions using the Pearson χ2 test; Spearman correlation (R) and partial correlation (Rрс) analyses were performed to adjust for the influence of age.
Results. Statistically significant associations of WC were identified: negative with estradiol and HDL-C levels, positive with PMD, TyG, glucose, TG, blood pressure, and insulin levels, with no associations with FSH. WC also showed a Spearman correlation with the TyG index (R=0.526; p<0.001), which correlated with age-dependent FSH (R=0.212; p<0.05) and independently with age-dependent estradiol (R=0.252; p<0.01) and PMD (R=0.338; p<0.001). FSH and estradiol levels correlated with MetS markers completely in an age-dependent manner. The associations of PMD with FSH and TyG were more stable, persisting after age adjustment.
Conclusions. Correlations of perimenopausal parameters clarify their influence on MetS components, with the additional effect of PMD as a parameter of reproductive aging in addition to chronological aging. The OT association complex, reflecting the importance of anthropometric indicators as predictors of metabolic disorders, clarifies the factors that shape OT during perimenopause, drawing attention to its early stages for timely preventive interventions.
Keywords: perimenopause, insulin resistance, TyG index, abdominal obesity, waist circumference, metabolic syndrome, cardiometabolic risk, incretin analogs.

About the Author

Dmitry S. Ruyatkin 1 , Lyudmila A. Ruyatkina 1 , Liliya V. Shcherbakova 2

1 Novosibirsk State Medical University, Novosibirsk, Russia

2 Institute of Internal and Preventive Medicine – a branch of the Institute of Cytology and Genetics, Novosibirsk, Russia

References

1. Clayton GL, Soares AG, Kilpi F et al. Cardiovascular health in the menopause transition: a longitudinal study of up to 3892 women with up to four repeated measures of risk factors. BMC Med 2022;20(1):299. DOI: 10.1186/s12916-022-02454-6
2. Uddenberg ER, Safwan N, Saadedine M et al. Menopause transition and cardiovascular disease risk. Maturitas 2024;185:107974. DOI: 10.1016/j.maturitas.2024.107974
3. Meloni A, Cadeddu C, Cugusi L et al. Gender Differences and Cardiometabolic Risk: The Importance of the Risk Factors. Int J Mol Sci 2023;24(2):1588. DOI: 10.3390/ijms24021588
4. Wang Y, Che Z, Huo Z et al. Metabolic Syndrome Evolution and Cardio-Kidney-Metabolic Multimorbidity: Implications for Targeted Prevention. JACC Adv 2025(6 Pt 2):101778. DOI: 10.1016/j.jacadv.2025. 101778
5. Orhan Ý, Koçak HS, Kaplan E. Determination of cardiometabolic risk in pre- and post-menopausal women. BMC Cardiovasc Disord 2025;25(1):399. DOI: 10.1186/s12872-025-04850-1
6. Liu J, Hao L, Lavie CJ. A Narrative Review of Cardiometabolic Profiles among U.S. Adults: Temporal Trends and Implications. Curr Cardiol Rep 2025;27(1):36. DOI: 10.1007/s11886-024-02179-3
7. Roa-Díaz ZM, Raguindin PF, Bano A et al. Menopause and cardiometabolic diseases: What we (don't) know and why it matters. Maturitas 2021, 152:48-56. DOI: 10.1016/j.maturitas.2021.06.01
8. Nappi RE, Chedraui P, Lambrinoudaki I, Simoncini T. Menopause: a cardiometabolic transition. Lancet Diabetes Endocrinol 2022;10(6):442-56. DOI: 10.1016/S2213-8587(22)00076-6
9. Peters BA, Lin J, Qi Q et al. Menopause Is Associated with an Altered Gut Microbiome and Estrobolome, with Implications for Adverse Cardiometabolic Risk in the Hispanic Community Health Study/Study of Latinos. mSystems 2022;7(3):e0027322. DOI: 10.1128/msystems.00273-22
10. Gurka MJ, Vishnu A, Santen RJ, DeBoer MD. Progression of Metabolic Syndrome Severity During the Menopausal Transition. J Am Heart Assoc 2016;5(8):e003609. DOI: 10.1161/JAHA.116.003609
11. Ciarambino T, Crispino P, Guarisco G, Giordano M. Gender Differences in Insulin Resistance: New Knowledge and Perspectives. Curr Issues Mol Biol 2023;45(10):7845-61. DOI: 10.3390/cimb45100496
12. Erdoðan K, Sanlier N. Metabolic Syndrome and Menopause: The Impact of Menopause Duration on Risk Factors and Components. Int J Womens Health 2024;16:1249-56. DOI: 10.2147/IJWH.S460645
13. De Paoli M, Zakharia A, Werstuck GH. The Role of Estrogen in Insulin Resistance: A Review of Clinical and Preclinical Data. The American Journal of Pathology. Am J Pathol 2021;191(9):1490-8. DOI: 10.1016/j.ajpath.2021.05.011
14. Stefanska A, Bergmann K, Sypniewska G. Metabolic Syndrome and Menopause: Pathophysiology, Clinical and Diagnostic Significance. Adv Clin Chem 2015;72:1-75. DOI: 10.1016/bs.acc.2015.07.001
15. Lee EJ, Keller-Ross ML. Menopause and its effects on autonomic regulation of blood pressure: Insights and perspectives. Auton Neurosci 2025;260:103295. DOI: 10.1016/j.autneu.2025.103295
16. Maas AHEM, Rosano G, Cifkova R et al. Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists. Eur Heart J 2021;42(10):967-84. DOI: 10.1093/eurheartj/ehaa1044
17. Nair AR, Pillai AJ, Nair N. Cardiovascular Changes in Menopause. Curr Cardiol Rev 2021;17(4):e230421187681. DOI: 10.2174/1573403X 16666201106141811
18. Lambrinoudaki I, Armeni E. Understanding of and clinical approach to cardiometabolic transition at the menopause. Climacteric 2024;27(1):68-74. DOI: 10.1080/13697137.2023.2202809
19. Stanciu S, Rusu E, Miricescu D et al. Links between Metabolic Syndrome and Hypertension: The Relationship with the Current Antidiabetic Drugs. Metabolites 2023;13(1):87. DOI: 10.3390/metabo 13010087
20. Rao X, Xin Z, Yu Q et al. Triglyceride-glucose-body mass index and the incidence of cardiovascular diseases: a meta-analysis of cohort studies. Cardiovasc Diabetol 2025;24(1):34. DOI: 10.1186/s12933-025-02584-0
21. Li Q, Wang X, Ni Y et al. Epidemiological characteristics and risk factors of T2DM in Chinese premenopausal and postmenopausal women. Lipids Health Dis 2019;18(1):155. DOI: 10.1186/s12944-019-1091-7
22. Mumusoglu S, Yildiz BO. Metabolic Syndrome During Menopause. Curr Vasc Pharmacol 2019;17(6):595-603. DOI: 10.2174/157016111 6666180904094149
23. Liao J, Wang L, Duan L et al. Association between estimated glucose disposal rate and cardiovascular diseases in patients with diabetes or prediabetes: a cross-sectional study. Cardiovasc Diabetol 2025;24(1):13. DOI: 10.1186/s12933-024-02570-y
24. Tahapary DL, Pratisthita LB, Fitri NA et al. Challenges in the diagnosis of insulin resistance: Focusing on the role of HOMA-IR and Tryglyceride/glucose index. Diabetes Metab Syndr 2022;16(8):102581. DOI: 10.1016/j.dsx.2022.102581
25. Porada D, Gołacki J, Matyjaszek-Matuszek B. Obesity in perimenopause - current treatment options based on pathogenetic factors. Endokrynol Pol 2023;74(6). DOI: 10.5603/ep.96679
26. Harraqui K, Oudghiri DE, Hannoun Z et al. Frequency of Metabolic Syndrome and Study of Anthropometric, Clinical and Biological Characteristics in Peri- and Postmenopausal Women in the City of Ksar El Kebir (Northern Morocco). Int J Environ Res Public Health 2022;19(10):6109. DOI: 10.3390/ijerph19106109
27. Harlow SD, Gass M, Hall JE et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive aging. Climacteric 2012;15(2):105-14. DOI: 10.3109/13697137.2011.650656
28. Руяткина Л.А., Руяткин Д.С., Исхакова И.С. Возможности и варианты суррогатной оценки инсулинорезистентности. Ожирение и метаболизм. 2019;16(1):27-33. DOI: 10.14341/omet10082
Ruyatkina L.A., Ruyatkin D.S., Iskhakova I.S. Opportunities and options for surrogate assessment of insulin resistance. Obesity and Metabolism 2019;16(1):27-33. DOI: 10.14341/omet10082 (in Russian).
29. Ruyatkina LA, Ruyatkin DS, Shcherbakova LV. Hormonal-metabolic trajectory of menopausal transition in a normoglycemic cohort of women with different blood pressure levels. Med Res Arch 2024;12(1). DOI: 10.18103/mra.v12i1.4972
30. El Khoudary SR, Aggarwal B, Beckie TM et al. American Heart Association Prevention Science Committee of the Council on Epidemiology and Prevention; and Council on Cardiovascular and Stroke Nursing. Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association. Circulation 2020;142(25):e506-e532. DOI: 10.1161/CIR.0000000000000912
31. Jeong HG, Park H. Metabolic Disorders in Menopause. Metabolites 2022;12(10):954. DOI: 10.3390/metabo12100954
32. Santilli F, D’Ardes D, Guagnano MT, Davi G. Metabolic Syndrome: Sex-Related Cardiovascular Risk and Therapeutic Approach. Curr Med Chem 2017;24(24):2602-27. DOI: 10.2174/0929867324666170710121145
33. Tepper PG, Randolph JF Jr, McConnell DS et al. Trajectory clustering of estradiol and follicle-stimulating hormone during the menopausal transition among women in the Study of Women's Health across the Nation (SWAN). J Clin Endocrinol Metab 2012;97(8):2872-80. DOI: 10.1210/jc.2012-1422
34. Moreau KL. Intersection between gonadal function and vascular aging in women. J Appl Physiol (1985) 2018;125(6):1881-7. DOI: 10.1152/japplphysiol.00117.2018
35. Cheng Y, Zhu H, Ren J et al. Follicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets. Nat Commun 2023;14(1):6991. DOI: 10.1038/s41467-023-42801-6
36. Xu C, He Z, Song Y et al. Atypical pituitary hormone-target tissue axis. Front Med 2023;17(1):1-17. DOI: 10.1007/s11684-022-0973-7
37. Song Y, Wang ES, Xing LL et al. Follicle-Stimulating Hormone Induces Postmenopausal Dyslipidemia Through Inhibiting Hepatic Cholesterol Metabolism. J Clin Endocrinol Metab 2016;101(1):254-63. DOI: 10.1210/jc.2015-2724
38. Guo Y, Zhao M, Bo T et al. Blocking FSH inhibits hepatic cholesterol biosynthesis and reduces serum cholesterol. Cell Res 2019;29(2):151-66. DOI: 10.1038/s41422-018-0123-6
39. Shahid I, Avenatti E, Titus A et al. Primary Prevention of Cardiovascular Disease in Women. Methodist Debakey Cardiovasc J 2024;20(2):94-106. DOI: 10.14797/mdcvj.1313
40. Hetherington K, Thomas J, Nicholls SJ et al. Unique cardiometabolic factors in women that contribute to modified cardiovascular disease risk. Eur J Pharmacol 2024;984:177031. DOI: 10.1016/j.ejphar. 2024.177031
41. Wu B, Fan B, Qu Y et al. Trajectories of Blood Lipids Profile in Midlife Women: Does Menopause Matter? J Am Heart Assoc 2023;12(22):e030388. DOI: 10.1161/JAHA.123.030388
42. Garcia-Carretero R, Vazquez-Gomez O, Gil-Prieto R, Gil-de-Miguel A. Insulin resistance is a cardiovascular risk factor in hypertensive adults without type 2 diabetes mellitus. Wien Klin Wochenschr 2024;136(3-4):101-9. DOI: 10.1007/s00508-023-02278-1
43. Welsh A, Hammad M, Piña IL, Kulinski J. Obesity and cardiovascular health. Eur J Prev Cardiol 2024;31(8):1026-35. DOI: 10.1093/eurjpc/ zwae025
44. Lazaridis A, Malliora A, Gkaliagkousi E. The Particularities of Arterial Hypertension in Female Sex: From Pathophysiology to Therapeutic Management. J Clin Med 2025;14(9):3137. DOI: 10.3390/jcm14093137
45. Liu X, Xu J, Wei D, Chen Y. Associations of Serum Follicle-Stimulating Hormone and Luteinizing Hormone Levels with Fat and Lean Mass during Menopausal Transition. Obes Facts 2023;16(2):184-93. DOI: 10.1159/000528317
46. Fenton A. Weight, Shape, and Body Composition Changes at Menopause. J Midlife Health 2021;12(3):187-92. DOI: 10.4103/jmh. jmh_123_21
47. Powell-Wiley TM, Poirier P, Burke LE et al. American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021;143(21):e984-e1010. DOI: 10.1161/CIR.0000000000000973
48. de Cuevillas B, Alvarez-Alvarez I, Riezu-Boj JI et al. The hypertriglyceridemic-waist phenotype as a valuable and integrative mirror of metabolic syndrome traits. Sci Rep 2021;11(1):21859. DOI: 10.1038/s41598-021-01343-x
49. Fenton A, Smart C, Goldschmidt L et al. Fat mass, weight and body shape changes at menopause – causes and consequences: a narrative review. Climacteric 2023;26(4):381-7. DOI: 10.1080/13697137.2023. 2178892
50. Golubeva JA, Sheptulina AF, Elkina AY et al. Which Comes First, Nonalcoholic Fatty Liver Disease or Arterial Hypertension? Biomedicines 2023;11(9):2465. DOI: 10.3390/biomedicines11092465
51. Ayesh H, Nasser SA, Ferdinand KC, Carranza Leon BG. Sex-Specific Factors Influencing Obesity in Women: Bridging the Gap Between Science and Clinical Practice. Circ Res 2025;136(6):594-605. DOI: 10.1161/CIRCRESAHA.124.325535
52. Mao L, Wang L, Bennett S et al. Effects of follicle-stimulating hormone on fat metabolism and cognitive impairment in women during menopause. Front Physiol 2022;13:1043237. DOI: 10.3389/fphys. 2022.1043237
53. Seto H, Toki H, Kitora S et al. Seasonal variations of the prevalence of metabolic syndrome and its markers using big-data of health check-ups. Environ Health Prev Med 2024;29:2. DOI: 10.1265/ehpm.23-00216
54. Ahuja M, Sharma JB, Perumal V et al. A Survey on Relation of Menopause to Metabolic Syndrome - SAFOMS STUDY (South Asian Federation of Menopause Societies) – Interim Analysis. J Midlife Health 2023;14(4):291-8. DOI: 10.4103/jmh.jmh_17_24
55. Aleksejeva S, Meija L, Zolovs M, Ciprovica I. Plasma Lipid Profile Among Perimenopausal Latvian Women in Relation to Dietary Habits. Nutrients 2025;17(2):243. DOI: 10.3390/nu17020243
56. Karaflou M, Goulis DG. Body composition analysis: A snapshot across the perimenopause. Maturitas 2024;180:107898. DOI: 10.1016/j.maturitas.2023.107898
57. Koskinas KC, Van Craenenbroeck EM, Antoniades C et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur J Prev Cardiol 2025;32(3):184-220. DOI: 10.1093/eurjpc/zwae279
58. Christensen S, Nelson C. Chronicity of obesity and the importance of early treatment to reduce cardiometabolic risk and improve body composition. Obes Pillars 2025;15:100175. DOI: 10.1016/j.obpill.2025. 100175
59. Chagas CL, da Silva NF, Rodrigues IG et al. Different factors modulate visceral and subcutaneous fat accumulation in adults: a single-center study in Brazil. Front Nutr 2025;12:1524389. DOI: 10.3389/fnut.2025. 1524389
60. Grosicki GJ, Dhurandhar NV, Unick JL et al. Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications. Curr Dev Nutr 2024;8(11):104486. DOI: 10.1016/j.cdnut.2024.104486
61. Jamal N, Hollabaugh W, Scott L, Takkouche S. Unravelling the ties that bind: The intersection of obesity, osteoarthritis, and inflammatory pathways with emphasis on glucagon-like peptide-1 agonists. Clin Obes 2025;15(1):e12700. DOI: 10.1111/cob.12700
62. Muzurović EM, Volčanšek Š, Tomšić KZ et al. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease-Current Evidence. J Cardiovasc Pharmacol Ther 2022;27:10742484221146371. DOI: 10.1177/1074248 4221146371
63. Chartrand DJ, Murphy-Després A et al. Overweight, Obesity, and CVD Risk: a Focus on Visceral/Ectopic Fat. Curr Atheroscler Rep 2022;24(4):185-95. DOI: 10.1007/s11883-022-00996-x
64. Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol 2021;20(1):225. DOI: 10.1186/s12933-021-01412-5
65. Луговик И.А., Бабина А.В., Арутюнян С.С. и др. Первый дженерик тирзепатида GP30931: физико-химическое и биологическое сходство с референтным лекарственным средством. Разработка и регистрация лекарственных средств. 2025;14(2):54-74. DOI: 10.33380/2305-2066-2025-14-2-2084
Lugovik I.A., Babina A.V., Arutyunyan S.S. et al. The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug. Drug development & Registration 2025;14(2):54-74. DOI: 10.33380/2305-2066-2025-14-2-2084 (in Russian). 
66. Rahmani Y, Derby CA, Santoro N et al. Menopause Is Associated with an Altered Gut Microbiome and Estrobolome, with Implications for Adverse Cardiometabolic Risk in the Hispanic Community Health Study/Study of Latinos. mSystems 2022;7(3):e0027322. DOI: 10.1128/msystems.00273-22
67. McClements L, Kautzky-Willer A, Kararigas G et al. The role of sex differences in cardiovascular, metabolic, and immune functions in health and disease: a review for “Sex Differences in Health Awareness Day”. Biol Sex Differ 2025;16(1):33. DOI: 10.1186/s13293-025-00714-7
68. Wu C, Ke Y, Nianogo RA. Trends in hyperinsulinemia and insulin resistance among nondiabetic US adults, NHANES, 1999–2018. J Clin Med 2025;14(9):3215. DOI: 10.3390/jcm14093215
69. Furrer R, Handschin C. Biomarkers of aging: from molecules and surrogates to physiology and function. Physiol Rev 2025;105(3):1609-94. DOI: 10.1152/physrev.00045.2024

For citation:Ruyatkin D.S., Ruyatkina L.A., Shcherbakova L.V. Beyond the menopause horizon: searching for the clinical onset of cardiometabolic risk. Clinical review for general practice. 2025; 6 (11): 96–106 (In Russ.). DOI: 10.47407/kr2025.6.11.00717


All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

  • About
  • Editorial board
  • Ethics
  • For authors
  • Author fees
  • Peer review
  • Contacts

oa
crossref
анри


  Indexing

Scopus
doaj
elibrary

Address of the Editorial Office:

127055, Moscow, s/m 37

Correspondence address:

115054, Moscow, Zhukov passage, 19, fl. 2, room XI


Managing Editor:

+7 (495) 926-29-83

id@con-med.ru